Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29451289 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL28918511 | 0.98 | SMN1; SMN2 (0.64) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL9018859 | 0.92 | KMT2A (0.60) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL11660382 | 0.87 | HPGD (0.70) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL862532 | 0.87 | TSHR (0.70) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL30388763 | 0.86 | EPHX1 (0.72) | SMN1; SMN2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL3831243 | 0.86 | EPHX1 (0.72) | SMN1; SMN2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL6543397 | 0.84 | EPHX1 (0.79) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL6464089 | 0.84 | KMT2A (0.61) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL5534456 | 0.84 | KMT2A (0.66) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115368281-B | PCVS synthesis process | 湖北丽康源化工有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-115368281-A | PCVS (Primary biliary cirrhosis) synthesis process | 湖北丽康源化工有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-113999232-A | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-9939454-B2 | Fluorogenic pH sensitive dyes and their method of use | Life Technologies Corporation (US) | 2018-04-10 | — | — | US | disclosed |
| US-9910051-B2 | Fluorogenic pH sensitive dyes and their method of use | Life Technologies Corporation (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160139158-A1 | FLUOROGENIC PH SENSITIVE DYES AND THEIR METHOD OF USE | Life Technologies Corporation | 2016-05-19 | — | — | US | disclosed |
| US-9333202-B2 | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150037834-A1 | FLUOROGENIC PH SENSITIVE DYES AND THEIR METHOD OF USE | Life Technologies Corporation | 2015-02-05 | — | — | US | disclosed |
| WO-1999026942-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1998034995-A1 | COMPOUNDS AND METHODS FOR DOPING LIQUID CRYSTAL HOSTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-08-13 | — | — | WO | disclosed |
| EP-0445926-B1 | Organic materials having sulfonamido linked poly(oxyalkylene) moieties and their preparation | MILLIKEN RES CORP (US) | 1996-08-21 | — | — | EP | disclosed |
| US-5240464-A | Organic materials having sulfonamido linked poly(oxyalkylene) moieties and their preparation | MILLIKEN RESEARCH CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0445926-A2 | Organic materials having sulfonamido linked poly(oxyalkylene) moieties and their preparation | MILLIKEN RESEARCH CORPORATION (US) | 1991-09-11 | — | — | EP | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0049711-B1 | PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES | BAYER AG (DE) | 1984-02-29 | — | — | EP | disclosed |
| EP-0049711-A1 | Process for the production of nitro-amino-benzenes | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
| US-4166069-A | PROCESS FOR THE PREPARATION OF 2-METHOXY-5-METHYLANILINE-4-SULPHONIC ACID | BAYER AKTIENGESELLSCHAFT (DE) | 1979-08-28 | — | — | US | disclosed |
| US-4151203-A | Process for the preparation of p-nitroaniline compounds by the alkaline hydrolysis of mixed anilides | EASTMAN KODAK COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | SMN1; SMN2 366/4885KMT2A 3434/4885MEN1 4615/4885 |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | SMN1; SMN2 366/4885KMT2A 3434/4885MEN1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.